UroGen Pharma Ltd.URGN stock score: 58/100

$31.73 · +6.51% · Scored Nov 19, 2026

Technical
54
Fundamental
58
News
53

The reading

UroGen Pharma (URGN) scores 58 out of 100, which reads neutral, higher than 69% of Healthcare stocks and 69% of the 4,118 US stocks we score.

The composite weights fundamentals 80% and technicals 20%: fundamentals read 58, technicals 54.

Among the fundamentals, Price Target at 100 and Revenue Growth (Quarterly) at 100 score highest, while Earnings Quality (Annual) at 0 weighs the most against it.

On the daily chart, trend-following indicators average 48 and contrarian oscillators 48.

News sentiment is neutral at 53; it is shown, not counted in the composite.

Since Aug 22, 2026 the composite has ranged from 44 to 58, and it is up 1 point over the period.

About UroGen Pharma

UroGen Pharma (URGN) is a biotechnology company focused on treatments for urothelial and other specialty cancers. Its products use a proprietary reverse-thermal hydrogel that is liquid when cold and turns into a gel at body temperature, letting the chemotherapy drug mitomycin stay in contact with tumors longer than a standard liquid would. JELMYTO treats low-grade upper tract urothelial cancer, which forms in the lining of the kidney and ureter. ZUSDURI treats recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer, giving patients an option that can avoid repeated surgery to remove tumors. The company is developing UGN-103, a next-generation version for bladder cancer, along with other pipeline programs. Urologists administer the products in clinics and hospitals, and UroGen earns money from product sales to specialty distributors and pharmacies, with reimbursement mainly from Medicare and commercial insurers.

UroGen’s products compete mainly with surgical removal of tumors, and more broadly with bladder cancer therapies from companies such as Johnson & Johnson and CG Oncology. Its edge rests on its hydrogel delivery technology, approved non-surgical treatments for low-grade disease and a specialized sales force calling on urologists. Investors who follow URGN stock tend to watch ZUSDURI sales growth, the number of treating sites and prescribers and the rate of repeat use. JELMYTO sales are closely followed. Progress of UGN-103 toward approval, operating losses, cash use and patent protection are other factors.

What’s driving the score

The strongest and weakest of the scorers that count toward URGN’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.

Fundamental

58

Pulling it up

  • Price target score compares the current stock price to analyst consensus targets.

  • Year-over-year revenue growth for each of the last four quarters, weighted toward the latest.

  • How the latest quarter's revenue compares with the average of the last four, plus a bonus for steady quarterly revenue.

Holding it back

  • Absolute profitability: whether the company is profitable, its net margin against the sector range, and how consistently it has been profitable over three years.

  • 5-year earnings growth evaluates long-term profit trajectory and consistency.

  • Return on Assets (ROA) shows how efficiently a company uses its assets to generate profit.

35 weighted scorers; 4 had no data today and are left out rather than counted as zero.

Technical · daily

44

Pulling it up

  • Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.

  • VWAP100

    Volume Weighted Average Price (VWAP) shows the average price weighted by volume.

  • ADX (14) measures how strong a trend is, and the DI lines give its direction: a strong uptrend scores high and a strong downtrend scores low.

Holding it back

  • Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.

  • Simple Moving Average (100-period) provides a longer-term perspective on price trends.

  • Where the close sits against its 100-day SMA.

61 weighted scorers; 4 had no data today and are left out rather than counted as zero.

News · shown, not counted

Global News
53

Technical score by timeframe

ChartScoreWeight
Hourly641
Daily443
Weekly542
Monthly642

Composite score, last 90 days

05010058Aug 22, 2026Nov 19, 2026Aug 22, 2026: 57Aug 23, 2026: 57Aug 24, 2026: 56Aug 25, 2026: 56Aug 26, 2026: 57Aug 27, 2026: 55Aug 28, 2026: 55Aug 29, 2026: 55Aug 30, 2026: 55Aug 31, 2026: 55Sep 1, 2026: 57Sep 2, 2026: 57Sep 3, 2026: 57Sep 4, 2026: 56Sep 5, 2026: 56Sep 6, 2026: 56Sep 7, 2026: 56Sep 8, 2026: 56Sep 9, 2026: 56Sep 10, 2026: 53Sep 11, 2026: 54Sep 12, 2026: 54Sep 13, 2026: 54Sep 14, 2026: 54Sep 15, 2026: 53Sep 16, 2026: 55Sep 17, 2026: 56Sep 18, 2026: 55Sep 19, 2026: 55Sep 20, 2026: 55Sep 21, 2026: 54Sep 22, 2026: 54Sep 23, 2026: 55Sep 24, 2026: 54Sep 25, 2026: 53Sep 26, 2026: 54Sep 27, 2026: 54Sep 28, 2026: 53Sep 29, 2026: 53Sep 30, 2026: 53Oct 1, 2026: 53Oct 2, 2026: 55Oct 3, 2026: 55Oct 4, 2026: 55Oct 5, 2026: 56Oct 6, 2026: 55Oct 7, 2026: 53Oct 8, 2026: 51Oct 9, 2026: 51Oct 10, 2026: 51Oct 11, 2026: 51Oct 12, 2026: 52Oct 13, 2026: 52Oct 14, 2026: 50Oct 15, 2026: 51Oct 16, 2026: 50Oct 17, 2026: 50Oct 18, 2026: 50Oct 19, 2026: 50Oct 20, 2026: 51Oct 21, 2026: 51Oct 22, 2026: 51Oct 23, 2026: 50Oct 24, 2026: 50Oct 25, 2026: 50Oct 26, 2026: 50Oct 27, 2026: 50Oct 28, 2026: 51Oct 29, 2026: 49Oct 30, 2026: 49Nov 1, 2026: 49Nov 2, 2026: 53Nov 3, 2026: 53Nov 4, 2026: 47Nov 5, 2026: 45Nov 6, 2026: 44Nov 7, 2026: 44Nov 8, 2026: 44Nov 10, 2026: 45Nov 11, 2026: 46Nov 12, 2026: 56Nov 13, 2026: 56Nov 14, 2026: 55Nov 15, 2026: 55Nov 16, 2026: 56Nov 17, 2026: 56Nov 18, 2026: 56Nov 19, 2026: 58
Show the daily numbers
DateComposite
Nov 19, 202658
Nov 18, 202656
Nov 17, 202656
Nov 16, 202656
Nov 15, 202655
Nov 14, 202655
Nov 13, 202656
Nov 12, 202656
Nov 11, 202646
Nov 10, 202645
Nov 8, 202644
Nov 7, 202644
Nov 6, 202644
Nov 5, 202645
Nov 4, 202647
Nov 3, 202653
Nov 2, 202653
Nov 1, 202649
Oct 30, 202649
Oct 29, 202649
Oct 28, 202651
Oct 27, 202650
Oct 26, 202650
Oct 25, 202650
Oct 24, 202650
Oct 23, 202650
Oct 22, 202651
Oct 21, 202651
Oct 20, 202651
Oct 19, 202650
Oct 18, 202650
Oct 17, 202650
Oct 16, 202650
Oct 15, 202651
Oct 14, 202650
Oct 13, 202652
Oct 12, 202652
Oct 11, 202651
Oct 10, 202651
Oct 9, 202651
Oct 8, 202651
Oct 7, 202653
Oct 6, 202655
Oct 5, 202656
Oct 4, 202655
Oct 3, 202655
Oct 2, 202655
Oct 1, 202653
Sep 30, 202653
Sep 29, 202653
Sep 28, 202653
Sep 27, 202654
Sep 26, 202654
Sep 25, 202653
Sep 24, 202654
Sep 23, 202655
Sep 22, 202654
Sep 21, 202654
Sep 20, 202655
Sep 19, 202655
Sep 18, 202655
Sep 17, 202656
Sep 16, 202655
Sep 15, 202653
Sep 14, 202654
Sep 13, 202654
Sep 12, 202654
Sep 11, 202654
Sep 10, 202653
Sep 9, 202656
Sep 8, 202656
Sep 7, 202656
Sep 6, 202656
Sep 5, 202656
Sep 4, 202656
Sep 3, 202657
Sep 2, 202657
Sep 1, 202657
Aug 31, 202655
Aug 30, 202655
Aug 29, 202655
Aug 28, 202655
Aug 27, 202655
Aug 26, 202657
Aug 25, 202656
Aug 24, 202656
Aug 23, 202657
Aug 22, 202657

Key facts

Market cap
$1.6B
Sector
Healthcare
Industry
Biotechnology
Beta
1.64
Risk grade (1–10)
2
Next earnings
Nov 4, 2026

Questions

What is URGN's stock rating today?

URGN scores 58/100 (Neutral) as of Nov 19, 2026: technical 54, fundamental 58, and news sentiment 53, which is shown but not counted. Scores are recomputed every night.

What does UroGen Pharma do?

UroGen Pharma (URGN) is a biotechnology company focused on treatments for urothelial and other specialty cancers. Its products use a proprietary reverse-thermal hydrogel that is liquid when cold and turns into a gel at body temperature, letting the chemotherapy drug mitomycin stay in contact with tumors longer than a standard liquid would.

Is URGN stock a buy?

The score is not a buy or sell recommendation. A 58 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.

How is the URGN score calculated?

96 weighted scorers feed it today: 35 fundamental, scored against Healthcare ranges, and 61 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.

Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.

Embed this score

A badge for a blog post, newsletter or README. It updates every night and links back here. More badges

URGN stock score

HTML

<a href="https://stocksscores.com/stocks/urgn/"><img src="https://stocksscores.com/stocks/urgn/badge.svg" alt="URGN stock score" height="20"></a>

Markdown

[![URGN stock score](https://stocksscores.com/stocks/urgn/badge.svg)](https://stocksscores.com/stocks/urgn/)